Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 1 min

Xylazine Reshapes the Sleep and Respiratory Consequences of Chronic Fentanyl Exposure in a Sex-Dependent Manner

AI Summary
  • Combined fentanyl and xylazine produce sex-dependent alterations in sleep architecture, including impaired NREMS recovery, altered REM dynamics, and reduced sleep bout duration.
  • Fentanyl-xylazine co-exposure exacerbates respiratory depression relative to fentanyl alone, with males showing greater vulnerability.
  • Co-administration elevates peripheral fibroblast growth factor 21, a hepatokine linked to reduced opioid preference, while no skin lesions were observed.
Summarise with AI (MRCPsych/FRANZCP)

bioRxiv [Preprint]. 2026 Sep 8:2026.09.02.748951. doi: 10.64898/2026.09.02.748951.

ABSTRACT

Recent shifts in the illicit fentanyl supply have led to widespread exposure to xylazine, yet the biological consequences of chronic fentanyl-xylazine co-exposure remain poorly understood. Here, we compared the behavioral and molecular effects of chronic exposures to fentanyl and xylazine both alone and in combination in male and female mice. Combined fentanyl-xylazine produced distinct, sex-dependent alterations in sleep architecture, including changes in NREMS recovery, REMS dynamics, and reduced sleep bout duration compared with fentanyl alone. The α 2 -adrenergic receptor antagonist yohimbine partially reversed these sleep alterations in a sex-dependent manner. Fentanyl-xylazine also exacerbated respiratory depression relative to fentanyl alone, particularly in males. In contrast, despite its prevalence in humans no skin lesions were observed. Molecular analyses revealed that fentanyl-xylazine co-administration leads to increased peripheral Fibroblast growth factor 21, a hepatokine linked to reduced opioid preference and alcohol consumption. Together, these findings demonstrate that xylazine substantially alters the physiological and neurobiological consequences of chronic fentanyl exposure in a sex-dependent manner, providing a preclinical framework for understanding the growing public health impact of fentanyl-xylazine co-use.

PMID:42818621 | PMC:PMC13622533 | DOI:10.64898/2026.09.02.748951

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

Save as PDF

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD